Business Wire

ADVA

18.2.2020 09:02:11 CET | Business Wire | Press release

Share
ADVA unveils industry’s most compact 100G edge demarcation solution

ADVA (FSE: ADV) today launched the industry’s most compact demarcation and aggregation technology, bringing cost-effective MEF 3.0-certified 100Gbit/s services to the network edge. The ADVA FSP 150-XG400 Series enables businesses and mobile network operators (MNOs) to easily scale their metro networks and tackle booming bandwidth demand. Specifically engineered to deliver MEF 3.0 Carrier Ethernet 100Gbit/s demarcation and 10Gbit/s service aggregation, the new product family features the market’s only uncompromised line-rate 100Gbit/s activation testing. It also supports hardware-based timing for ultra-precise frequency and phase synchronization, making it the ideal choice for radio access networks. With its high-density and environmentally hardened design, the ADVA FSP 150-XG400 Series is also easy to deploy in space-restrictive locations with no temperature control – a key requirement for the rollout of 5G connectivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200218005165/en/

“The arrival of 5G is bringing unprecedented data speeds, but mobile applications can only be as fast as the backhaul network. That’s why MNOs are now looking to upgrade their access infrastructure from 10Gbit/s to 100Gbit/s line rates. Our FSP 150-XG400 Series supports a smooth and extremely cost-effective migration to higher capacity while also enabling the distribution of precise network synchronization that next-generation services require,” said Stephan Rettenberger, SVP, marketing and investor relations, ADVA. “With their compact, ETSI-compliant design, our FSP 150-XG400 devices remove the need for deep shelves and excessive rack height units. This makes it easy and affordable to seamlessly upgrade from 1Gbit/s to 10Gbit/s or even 100Gbit/s service delivery. What’s more, the new solutions feature integrated testing capabilities, so operators don’t have to bother with expensive high-bitrate testing equipment.”

The ADVA FSP 150-XG400 Series of high-density service aggregation solutions is the ultimate tool for scaling edge networks for future wholesale, business, mobile fronthaul and backhaul service needs. Available in a 1RU or 2RU form factor, the unprecedentedly compact and highly versatile product range features 1, 10, 25, 40 or 100GbE interfaces. Each device comes with carrier-class Ethernet OAM and Y.1564 feature sets, including unique full line-speed activation testing for services up to 100Gbit/s. The ADVA FSP 150-XG400 Series supports network overlay capabilities for the delivery of MEF services over IP networks. It also provides standard SDN interfaces and can be directly controlled from open source and commercial SDN controllers. Able to withstand an extended temperature range, the ADVA FSP 150-XG400 Series avoids the high cost of air conditioning, enabling ease of deployment even in extreme environments.

“Our newest product family removes all the roadblocks and makes the task of transforming metro networks simple. With our FSP 150-XG400 Series delivering high-density demarcation and aggregation, businesses can expand and embrace the potential of IoT, and operators can deliver the next level of resilient SLA-based Carrier Ethernet services,” commented James Buchanan, GM, Edge Cloud, ADVA. “No other solution available offers such high port count, full testing capabilities and comprehensive network synchronization features with this level of design density. Our devices also provide proven OAM capabilities as well as fully automated service activation. Whether you need high-speed connectivity for cloud-centric business applications or building your enterprise IoT architecture, our FSP 150-XG400 Series has you covered.”

Watch this video for more information on the FSP 150-XG400 Series: https://youtu.be/bCzD9ffS0N8 .

Further details are also available in these slides: https://adva.li/fsp-150-xg400-series-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

Published by:
ADVA Optical Networking SE, Munich, Germany

www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye